Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 86 Breast Neoplasms 68 Triple Negative Breast Neoplasms 32 Prostatic Neoplasms 32 Fallopian Tube Neoplasms 25 Neoplasms 23 Neoplasm Metastasis 21 Pancreatic Neoplasms 18 Endometrial Neoplasms 18 Small Cell Lung Carcinoma 13 Carcinoma, Ovarian Epithelial 11 Carcinoma, Non-Small-Cell Lung 10 Stomach Neoplasms 9 Sarcoma 9 Recurrence 9 Lung Neoplasms 9 Fanconi Anemia, Complementation Group D1 9 Squamous Cell Carcinoma of Head and Neck 8 Glioma 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Glioblastoma 7 Colorectal Neoplasms 6 Metastatic Castration-resistant Prostate Cancer 5 Lymphoma, Non-Hodgkin 5 Cholangiocarcinoma 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Solid Tumors 4 Osteosarcoma 4

Interventions

olaparib 1 liposomal doxorubicin 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Ovarian Neoplasm Epithelial × olaparib × Clear all

NCT04780945 2026-02-17

FAB

Leiden University Medical Center

Phase 2 Terminated

Ovarian Neoplasm Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡